drugsTreatmentPhase 2

Spevatamig

aka Spevatamig (PT886)

Spevatamig is an experimental bispecific antibody from Phanes Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer, aimed at Claudin 18.2 and CD47.

Spevatamig (PT886) is a bispecific antibody developed by Phanes Therapeutics. Its targets are Claudin 18.2 and CD47. ClinicalTrials.gov describes the intervention as: Spevatamig (PT886) monotherapy, a novel bispecific antibody that targets Claudin 18.2 and CD47. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, pancreatic ductal adenocarcinoma and biliary tract cancer. The largest, NCT05482893, plans to enrol 258 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.

How it works, step by step · animated schematic, not to scale; chosen from the modality "bispecific antibody"

Bispecific antibodies →

Modality

bispecific antibody

Mechanism

Bispecific antibody directed at Claudin 18.2 and CD47, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

Brand / code

PT886

Trials

top

Trials recruiting now

Recruiting trials near you · live from ClinicalTrials.gov

Spevatamig

intervention: Spevatamig

Open on ClinicalTrials.gov →

within

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.